摘要
背景:全球肺癌发病率呈上升趋势。主要危险因素是烟草暴露量增加,被动吸烟,蔬菜和水果消耗减少以及职业接触石棉,砷和铬。肺癌的病理生理学是复杂的,不是很清楚。各种微RNA,基因和通路与肺癌有关。涉及肺癌的基因产生涉及细胞生长,分化,不同细胞周期,凋亡,免疫调节,肿瘤扩散和进展的蛋白质。河马途径(也被称为Salvador-Warts-Hippo途径)是癌症中最新出现的概念。 Hippo途径通过其对细胞增殖和凋亡的作用在控制组织和器官的大小方面起着重要的作用。 目的:在本文中,我们重点介绍了哺乳动物Hippo通路,其核心成员,上游调节因子,下游效应物和肺癌耐药情况。 结果:Mer与细胞表面乙酰透明质酸受体CD44的特异性相互作用在细胞接触抑制中是至关重要的,从而激活Hippo通路。转录辅激活物YAP和TAZ(也称为WWTR1,是果蝇Yki的同系物)是增殖和凋亡的重要调节剂,并且作为Hippo途径的主要下游效应物。 Hippo通路上游调节因子NF2的突变与癌症有关。 结论:靶向YAP和TAZ可能对未来的药物输送和治疗非常重要
关键词: 细胞增殖,凋亡,河马途径,肺癌,基因,药物输送
图形摘要
Current Drug Targets
Title:The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications
Volume: 18 Issue: 16
关键词: 细胞增殖,凋亡,河马途径,肺癌,基因,药物输送
摘要: Background: The incidence of lung cancers has increased globally. Increased exposure to tobacco, passive smoking, less consumption of vegetables and fruits and occupational exposure to asbestos, arsenic and chromium are the main risk factors. The pathophysiology of lung cancer is complex and not well understood. Various microRNAs, genes and pathways are associated with lung cancers. The genes involved in lung cancers produce proteins involved in cell growth, differentiation, different cell cycles, apoptosis, immune modulation, tumor spread and progression. The Hippo pathway (also known as the Salvador-Warts-Hippo pathway) is the latest emerging concept in cancers. The Hippo pathway plays an important role in controlling the size of the tissue and organ by virtue of its action on cell proliferation and apoptosis.
Objective: In the present review, we highlight the mammalian Hippo pathway, role of its core members, its upstream regulators, downstream effectors and the resistance cases in lung cancers.
Results: Specific interaction of Mer with cell surface hyaluronan receptor CD44 is vital in cell contact inhibition, thereby activating Hippo pathway. Both transcription co-activators YAP and TAZ (also known as WWTR1, being homologs of Drosophila Yki) are important regulators of proliferation and apoptosis, and serve as major downstream effectors of the Hippo pathway. Mutation of NF2, the upstream regulator of Hippo pathway is linked to the cancers.
Conclusion: Targeting YAP and TAZ may be important for future drug delivery and treatment.
Export Options
About this article
Cite this article as:
The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications, Current Drug Targets 2017; 18 (16) . https://dx.doi.org/10.2174/1389450117666160907153338
DOI https://dx.doi.org/10.2174/1389450117666160907153338 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Correlation Between <i>BCL2</i> and <i>Mcl1</i> Single Nucleotide Polymorphisms and Chemotherapy Response in Jordanian Patients with Colorectal Cancer
Current Pharmaceutical Biotechnology Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy Advanced Microfluorescence Methods in Monitoring Intracellular Uptake of “Antisense” Oligonucleotides
Current Organic Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued) Anti-Tumor Effect of AlkB Homolog 3 Knockdown in Hormone- Independent Prostate Cancer Cells
Current Cancer Drug Targets ERGIC3 Silencing Additively Enhances the Growth Inhibition of BFA on Lung Adenocarcinoma Cells
Current Cancer Drug Targets EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Combined Effect of Anti-Angiogentic Agents, Angiotensin Type 1 Receptor Antagonists and Radiation Therapy
Current Signal Transduction Therapy Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design
Current Medicinal Chemistry Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Genetic Instability Influences Drug Response in Cancer Cells
Current Drug Targets Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results
Reviews on Recent Clinical Trials Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets